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Does endometrial scratching increase the
rate of spontaneous conception in couples
with unexplained infertility and a good
prognosis (Hunault > 30%)? Study protocol
of the SCRaTCH-OFO trial: a randomized
controlled trial
B. N. Bui1*, H. L. Torrance1, C. Janssen2, B. Cohlen3, J. P. de Bruin4, J. E. den Hartog5, P. J. Q. van der Linden6,
K. L. Deurloo7, J. W. M. Maas8, R. van Oppenraaij9, A. Cantineau10, C. B. Lambalk11, H. Visser12, E. Brinkhuis13,
J. van Disseldorp14, B. C. Schoot15, C. Lardenoije16, M. van Wely17, M. J. C. Eijkemans1 and F. J. M. Broekmans1
Abstract
Background: In the Netherlands, couples with unexplained infertility and a good prognosis to conceive spontaneously
(i.e. Hunault > 30%) are advised to perform timed intercourse for at least another 6months. If couples fail to conceive
within this period, they will usually start assisted reproductive technology (ART). However, treatment of unexplained
infertility by ART is empirical and can involve significant burdens. Intentional endometrial injury, also called ‘endometrial
scratching’, has been proposed to positively affect the chance of embryo implantation in patients undergoing in vitro
fertilization (IVF). It might also be beneficial for couples with unexplained infertility as defective endometrial receptivity
may play a role in these women. The primary aim of this study is to determine whether endometrial scratching increases
live birth rates in women with unexplained infertility.
Method: A multicentre randomized controlled trial will be conducted in Dutch academic and non-academic hospitals
starting from November 2017. A total of 792 women with unexplained infertility and a good prognosis for spontaneous
conception < 12months (Hunault > 30%) will be included, of whom half will undergo endometrial scratching in the
luteal phase of the natural cycle. The women in the control group will not undergo endometrial scratching. According to
Dutch guidelines, both groups will subsequently perform timed intercourse for at least 6months. The primary endpoint is
cumulative live birth rate. Secondary endpoints are clinical and ongoing pregnancy rate; miscarriage rate; biochemical
pregnancy loss; multiple pregnancy rate; time to pregnancy; progression to intrauterine insemination (IUI) or IVF;
pregnancy complications; complications of endometrial scratching; costs and endometrial tissue parameters associated
with reproductive success or failure. The follow-up duration is 12months.
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Discussion: Several small studies show a possible beneficial effect of endometrial scratching in women with unexplained
infertility trying to conceive naturally or through IUI. However, the quality of this evidence is very low, making it unclear
whether these women will truly benefit from this procedure. The SCRaTCH-OFO trial aims to investigate the effect of
endometrial scratching on live birth rate in women with unexplained infertility and a good prognosis for spontaneous
conception < 12months.
Trial registration: NTR6687, registered August 31st, 2017.
Protocol version: Version 2.6, November 14th, 2018.
Keywords: Endometrial injury, Endometrial scratching, Endometrial scratch, Unexplained infertility, Endometrial receptivity,
Implantation failure, Hunault > 30%, Expectant management
Background
Unexplained infertility is diagnosed in up to 50% of in-
fertile couples when standard fertility investigations have
failed to detect any gross abnormality [1–3]. Uncertainty
about the underlying reasons of the infertility often leads
to use of empirical treatment that can involve significant
physical, psychological and financial burdens [4]. Hence
prediction models have been developed to distinguish
subfertile couples with a poor prognosis for spontaneous
pregnancy, for whom fertility treatment is thought to in-
crease their chance of conception, from subfertile cou-
ples who still have a good prognosis to conceive
spontaneously [5]. In the Netherlands, the prediction
model developed by Hunault et al. (2004) is used to pre-
dict the chance of spontaneous pregnancy within 1 year.
As stated in Dutch guidelines [3], couples with unex-
plained infertility and a prognosis according to Hunault
of > 30%, i.e. a good prognosis, are advised to perform
timed intercourse for at least another 6 months. If cou-
ples fail to conceive within 6 months to a year, they will
usually start assisted reproductive technology (ART), i.e.
intrauterine insemination (IUI) or in vitro fertilization
(IVF) [3]. IUI or IVF treatment for this diagnosis, how-
ever, is empirical and is mainly done due to the perceived
need to intervene to address unexplained infertility.
In previous research it has been postulated that de-
fective endometrial receptivity, with altered expression
of adhesive molecules and immunological factors, could
be a contributing factor in the aetiology of unexplained
infertility [4, 6–9]. At present, moderate-quality evi-
dence indicates that endometrial injury (‘scratching’) is
associated with an improvement in live birth rates
(LBR) in women undergoing IVF with repeated failed
embryo transfers [10]. Several hypotheses supporting
the positive effect of scratching on pregnancy rates have
been proposed, but the exact mechanism remains un-
clear [11]. The endometrial injury is thought to incite
changes, like induction of decidualization and immuno-
logic responses, which result in improved endometrial re-
ceptivity [10]. Since defective endometrial receptivity may
be a cause of subfertility in couples diagnosed with
unexplained infertility, scratching may be an effective
therapy for these couples. Although the majority of
studies showed a positive effect of scratching on preg-
nancy outcomes in women undergoing IVF, some re-
cent studies did not find endometrial scratching to be
effective in improving pregnancy outcomes in IVF
[12, 13]. As significant clinical heterogeneity in study
populations exist between studies, the applicability of
the evidence may vary in different subgroups of sub-
fertile women [10].
The effectiveness of scratching in couples trying to
conceive through sexual intercourse or IUI was re-
cently summarized in a review [14]. The main conclu-
sion was that scratching may have a beneficial effect
on the chance of conceiving, but that published stud-
ies have important limitations. Therefore these results
should be interpreted with caution. Since publication
of this review, one other study on endometrial injury
in women with unexplained infertility has been pub-
lished, reporting a non-significant difference in clin-
ical pregnancy rates (CPR) between the intervention
and control group (16.7 vs. 11.7%) [15]. Notably, this
study was not adequately powered to detect the ob-
served difference; a difference which may be clinically
relevant. Furthermore, none of the published studies
reported live birth rate as an outcome parameter,
which is the most important outcome for a couple
trying to conceive. Finally, there remains a paucity of
evidence on the duration of the effect of endometrial
scratching, making it unclear for how long the benefi-
cial effect of the scratch is sustained. These observa-
tions underline the need for more robust studies on
this topic.
The primary aim of the SCRaTCH-OFO study is to de-
termine whether endometrial scratching in the natural
cycle in women with unexplained infertility increases the
chance of live birth. Parallel to this, it aims to evaluate if
endometrial scratching leads to a decreased use of fertility
treatment and costs needed to achieve a live birth. Finally,
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the RCT contains a nested cohort study in which endomet-
rial samples will be banked to determine characteristics as-
sociated with reproductive success or failure within 12
months of follow-up.
Method
Study objective & design
The aim of this study is to evaluate whether endometrial
scratching increases the chance of live birth in women
with unexplained infertility and a good prognosis to con-
ceive spontaneously (Hunault > 30%). Furthermore, the
study seeks to determine endometrial characteristics cor-
relating with (un) successful implantation and to develop
endometrial organoids.
The SCRaTCH-OFO study is a multicentre randomized
controlled trial (RCT) coordinated by the University
Medical Centre Utrecht (UMC Utrecht, The Netherlands),
which will be performed within the Dutch Consortium for
Healthcare Evaluation and Research in Obstetrics and
Gynecology. A prospective cohort study is embedded
within the multicentre RCT, in which the endometrial bi-
opsy will be banked for determination of characteristics as-
sociated with reproductive success or failure and for
development of endometrial organoids that will open pos-
sibilities for further research into endometrium related dis-
orders. Some of the study methods of this trial will be
comparable to those previously described in the study
protocol of our other scratching trial, in which scratching
is performed in women undergoing IVF/intracytoplasmic
sperm injection (ICSI) cycles [16].
Study setting
Coordinating hospital, trial coordinator
University Medical Centre Utrecht, Utrecht, prof. dr. F.J.M.
Broekmans.
Participating hospitals, local trial coordinators
Catharina Hospital, Eindhoven, prof. dr. B.C. Schoot.
Deventer Hospital, Deventer, dr. P.J.Q. van der Linden.
Diakonessenhuis, Utrecht, dr. K.L. Deurloo.
Groene Hart Hospital, Gouda, dr. C. Janssen.
Isala Fertility Clinic, Zwolle, dr. B.J. Cohlen.
Jeroen Bosch Hospital, ‘s Hertogenbosch, dr. J.P. de Bruin.
Laurentius Hospital, Roermond, drs. C. Lardenoije.
Maasstad Hospital, Rotterdam, dr. R. van Oppenraaij.
Maastricht University Medical Centre +, Maastricht,
dr. J.E. den Hartog.
Máxima Medical Centre, Veldhoven, dr. J.W.M. Maas.
Meander Medical Centre, Amersfoort, drs. E.A. Brinkhuis.
St. Antonius Hospital, Nieuwegein, dr. J. van Disseldorp.
Tergooi Hospital, Hilversum, drs. H. Visser.
University Medical Centre Groningen, Groningen, dr.
A. Cantineau.
Vrije Universiteit Medical Centre, Amsterdam, prof.
dr. C.B. Lambalk.
Study population
Women from couples diagnosed with unexplained infer-
tility and a Hunault of > 30%, who have been advised to
continue timed intercourse during at least 6 months, are
eligible. Inclusion criteria are as follows: female age be-
tween 18 and 38 years; primary or secondary infertility
lasting at least 12 months; a regular menstrual cycle (de-
fined as a mean cycle length of 21–35 days); at least one
patent tube (diagnosed by negative Chlamydia antibody
titre (CAT) and absence of risk factors for tubal disease,
and/or diagnosed by hysterosalpingography or diagnostic
laparoscopy); total motile sperm count > 3 million and a
normal transvaginal ultrasound, which is defined as the
absence of visible intracavitary pathology (e.g. polyps or
intramural myomas with distortion of the uterine cavity).
Exclusion criteria are: a history of lower abdominal or
pelvic infection, a higher chance of intra-abdominal in-
fection due to intestinal surgery, endometriosis grade 3
and 4, previous caesarean section with niche develop-
ment, recurrent miscarriage (defined as ≥2 pregnancy
losses prior to 20 weeks of gestation), the presence of
untreated unilateral or bilateral hydrosalpinx, previous
endometrial scratching, meno-metrorrhagia, and un-
treated endocrine disorders.
Study endpoints
The primary endpoint is cumulative live birth rate, of
which the status of ‘ongoing pregnancy’ should be
achieved within 12 months after randomization, and is
defined as the delivery of at least one live fetus ≥24
weeks of gestation. Secondary endpoints include 1) on-
going pregnancy rate, defined as the detection of a fetal
heartbeat on ultrasound at a gestational age of 10–12
weeks; 2) clinical pregnancy rate, defined as a gesta-
tional sac visualized on ultrasound; 3) miscarriage rate,
defined as a demise of an intrauterine pregnancy con-
firmed by ultrasound or histology; 4) biochemical preg-
nancy loss, defined as a spontaneous pregnancy demise
after serum or urinary bèta-hCG had been detected,
without an ultrasound evaluation; 5) multiple preg-
nancy rate; 6) time to pregnancy, defined as the time
from randomization till a positive pregnancy test; how-
ever, only pregnancies that will reach the ‘ongoing’ sta-
tus will be included in the analysis; 7) progression to
IUI or IVF treatment; 8) pregnancy complications; 9)
complications of endometrial scratching (e.g. abnormal
bleeding, abnormal vaginal discharge, abdominal pain,
fever); 10) costs; 11) endometrial tissue parameters as-
sociated with reproductive success or failure, such as
endometrial gene expression profiles (EGPs).
Bui et al. BMC Pregnancy and Childbirth          (2018) 18:511 Page 3 of 9
Sample size calculation
A total of 792 women will be included in the RCT of
which we expect 150 to be included in the embedded
study. Based on previous studies, the estimated difference
in live birth rate is at least 10% between the patients with
and without endometrial scratch (live birth rate respect-
ively 45% vs. 35%).To detect such a difference with 80%
power, 396 patients are needed per study arm, resulting in
792 patients in total. This number takes into account an
estimated dropout rate of 5%.
Recruitment, consent and randomization
Eligible women will be given oral and written informa-
tion about the study by their gynaecologist or fertility
physician. Subsequently, these women will receive add-
itional counselling by the investigator or research nurse
after 1 week to allow the women to make an informed
decision on trial participation. To participate in the em-
bedded study, patients will give broad consent to the use
of their endometrial sample and data (i.e. for storing tis-
sue in the Biobank to determine EGPs and to develop
endometrial organoids). After obtaining written in-
formed consent, the patient will be randomly allocated
to either the scratch procedure or no scratch procedure.
Randomization is performed by a third party with a
web-based randomization program using random blocks
with block sizes of 2, 4 and 6. Due to the nature of the
intervention, patients and physicians are not blinded and
a sham intervention will not be performed. A survey
among women participating in a RCT comparing endo-
metrial scratching to a placebo procedure, showed that
participants allocated to the scratching arm were not ad-
equately blinded due to the discomfort they experienced
during the procedure, whereas the sham intervention
group was in fact less likely to guess their trial allocation
(unpublished thesis by Lensen). However, the guess of
trial allocation was not associated with the probability of
committing protocol violations or the pattern and timing
of intercourse (unpublished thesis by Lensen). Further-
more, a sham procedure could expose the control group
to some degree of endometrial scratching, thereby pos-
sibly interfering with the study outcome.
Study procedure
In the intervention group, an endometrial scratch will be
performed once before starting 6 months of timed inter-
course, during the luteal phase of the natural cycle.
Women are instructed to use urinary ovulation prediction
tests that detect the putative luteinizing hormone (LH)
surge (Ovulady, Clindia Benelux B.V., The Netherlands).
The scratch will be performed 6 or 7 days after a positive
urine ovulation test by a dedicated gynaecologist or fertil-
ity physician. If scheduling on this day is impossible then
the scratch can also be planned 5 or 8 days after a positive
ovulation test. Women will receive instructions that they
need to make sure that they are not pregnant in the
scratch cycle (no sexual intercourse or sexual intercourse
with appropriate contraceptive methods (e.g.condoms)).
After cleansing of the cervix with betadine, an endometrial
biopsy catheter will be introduced into the cervix up to
the uterine fundus. In most cases this will be a Pipelle de
Cornier® biopsy catheter, but the type of biopsy catheter
may vary per participating centre. The piston will be
drawn back to the end of the biopsy catheter. Then the
catheter is slowly retracted while rotating over several
ranges of 360 degrees during 1 to 2min. The protocol dif-
fers slightly for the subgroup of whom endometrial tissue
will be stored. Firstly, a sterile gown, gloves and cap will
be worn during the procedure in order to minimalize
RNase contamination. Secondly, cleaning of the cervix will
not be performed with betadine but with sterile saline so-
lution (sodium chloride 0.9%) because the outcomes of
RNA analysis could be affected by betadine. In order to
minimalize RNase contamination, sterile gloves are chan-
ged for new gloves directly after the procedure. The endo-
metrial tissue will be divided into three equal parts and
each part will be stored in a Tissue Sampling Storage Tube
(3ml, Cat. No. 68–4000-00, Fluid X). In the coordinating
centre (UMC Utrecht) and in one of the participating cen-
tres (Diakonessenhuis), two tubes will be snap-frozen in
liquid nitrogen and one tube will be used to collect tissue
for slow freezing of cells for organoid development. In the
other tissue-storing centres, three tubes will be snap-fro-
zen. The process of snap-freezing is performed within
maximally 3min from taking the biopsy. Subsequently,
the snap-frozen tissue will be stored in freezers at − 80 °C
until later determination of RNA profiles. Due to rapid de-
velopments in the field of genetics, the suited gene sets
and techniques will be determined at the time of tissue
analysis. The endometrial tissue intended for development
of endometrial organoids will first be slow-frozen in
medium containing dimethylsulfoxide (DMSO) and then
stored in liquid nitrogen at − 196 °C until later formation
of endometrial organoids. For this latter procedure the
technique published by Boretto et al. (2017) [17] will be
used.
Both the intervention and control group will undergo
at least 6 months of timed intercourse from the moment
of randomization. An overview of the study design and a
study time schedule can be found in respectively Fig. 1
and Fig. 2.
Follow-up
The follow-up duration is 12 months from the moment
of randomization. Each centre registers whether a pa-
tient has conceived during the follow-up period. When a
woman has become pregnant, she will undergo ultra-
sounds at 7–8 weeks and 10–12 weeks of gestation, after
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Fig. 1 Study flowchart. LH, luteinizing hormone. LN2, liquid nitrogen. UMCU, University Medical Centre Utrecht. IUI, intrauterine insemination. IVF,
in vitro fertilization. EGP, endometrial genetic profile. The boxes in pink apply to the nested cohort study
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which she will continue her prenatal visits with her mid-
wife or gynaecologist. The outcome of her pregnancy
will be obtained after her due date by a structured
questionnaire.
Data on all pregnancies and further fertility treat-
ment(s) within 12 months after randomization will be
obtained by a structured questionnaire. If available, this
information will also be extracted from the electronic
patient file.
Monitoring
Monitoring will be performed by a monitor from the
Dutch Consortium for Healthcare Evaluation in Obstet-
rics and Gynaecology. Furthermore, we have installed a
Data and Safety Monitoring Board (DSMB) from the
Dutch Consortium for Healthcare Evaluation and Re-
search in Obstetrics and Gynecology. Roles of the DSMB
include monitoring for evidence of treatment harm, such
as serious adverse events, and advising on continuation
or termination of the trial. Interim analyses have not
been planned.
Data collection and data analysis
Data will be collected in a web based registration system.
Database cleaning will consist of internal consistency
checks and identification of database entries outside ex-
pected ranges. Analysis will primarily be conducted accord-
ing to the intention-to-treat principle. In case many women
allocated to the intervention group ended up not having
the scratch procedure (or vice versa), a per-protocol
Fig. 2 Study time schedule according to SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials)-t1, pre-study period. t0,
allocation. t1, post-allocation period; women allocated to the endometrial scratch will undergo this procedure in the same or next month after
randomization, in the luteal phase of the natural cycle (6 to 7 days after a positive ovulation test). t2, 12 months after allocation, at which a follow-
up questionnaire will be sent to all women who have completed 12months of follow-up. t3, period in which follow-up of women with an
ongoing pregnancy, within 12 months after randomization, will continue until live birth. t4, close-out period. SAE, severe adverse events
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analysis may also be performed to clarify whether there
may have been an underestimation of the magnitude of ef-
fect. The researchers performing the data collection and
data analysis are not blinded to group allocation.
SPSS Statistics (IBM Corporation, Armonk, NY,
United States), R (R Foundation, New Zealand) and
Excel (Microsoft, Washington, United States) will be
used to perform the statistical analysis. The primary and
secondary outcome variables (except the costs, of which
analysis is described below) will be compared between
the treatment arms and expressed as relative risk with
95% confidence interval. A p-value less than 0.05 will be
considered to indicate a statistically significant difference.
Cost-effectiveness analysis
A cost-effectiveness analysis covering a period of 12
months will be performed parallel to the clinical trial for
economic evaluation, which is designed from both a health-
care and societal perspective. This cost-effectiveness ana-
lysis will be based on live birth rate and average costs per
patient, taking into account any additional fertility treat-
ments patients undergo during these 12months. The im-
pact on patient’s life will be expressed in quality-adjusted
life years (QALY). A decision model will be used to evaluate
the optimal strategy, taking into account the time to
pregnancy, (in) direct costs and estimated QALY. Add-
itionally, the incremental cost-effectiveness ratio (ICER)
and long-term costs, such as delivery and perinatal
costs, will be determined. Sensitivity analysis will define
robustness of the results.
Discussion
Since a study in 2003 [18] reported improved implant-
ation rates after endometrial scratching, this procedure
has been getting increasing global attention. Even
though conclusive scientific evidence on its beneficial ef-
fects is still lacking, endometrial scratching is frequently
being performed in women with subfertility [16]. While
this intervention might be favourable for patients under-
going IVF, the effectiveness remains unclear for women
with unexplained infertility trying to conceive naturally
or through IUI. Studies to date show a possible benefi-
cial effect of endometrial scratching in the latter group
of women [14]. However, the quality of this evidence is
very low and therefore these results should be inter-
preted with caution. To give clarity on this topic, robust
studies are needed.
If these studies can confirm a favourable effect of
endometrial scratching in increasing the live birth rate,
this intervention could be offered as a simple and
cost-effective treatment for unexplained infertility. Con-
sequently, this potentially avoids some patients undergoing
more expensive and invasive treatments such as IVF [19].
On the contrary, if further studies show that there is no
beneficial effect of endometrial scratching on live birth rate
in women with unexplained infertility, this group should
not undergo an intervention with additional costs and po-
tential risks as pain and infection.
The current study will evaluate the effect of endomet-
rial scratching on live birth in women with unexplained
infertility who are trying to conceive spontaneously. In
addition, this study seeks to identify whether endomet-
rial genetic profiles (EGPs) can predict the chance of
reproductive failure within one year in couples with unex-
plained subfertility, as Koot et al. (2016) have shown that
an endometrial 303-gene expression profile can predict re-
peated implantation failure (RIF) in women undergoing
IVF/ICSI (PPV 100%) [20]. Defective endometrial receptiv-
ity may contribute to the aetiology of unexplained infertil-
ity. Therefore identifying an EGP, that is related to impaired
endometrial receptivity, could help clinicians in counselling
and guiding treatment of women with unexplained infertil-
ity. Due to rapid developments in the field of genetics, we
have not determined the exact design for analysis of these
EGPs yet. As the strategy might implement some new tech-
niques or new genetic markers, it will be finalized later.
Until then, tissue will be stored for future research. Lastly,
development of endometrial organoids will be part of the
embedded study. In the past decade there has been a redis-
covery of organoids, which are three-dimensional (3D),
self-organizing and genetically stable cell cultures with cell
types that resemble the tissue of origin [21–23]. One of
their most valuable features is that organoids recapitulate
key structural and functional properties of the specific
organ they have been derived from [22]. Consequently,
patient-derived organoids offer possibilities to mimic path-
ologies in a dish and develop personalized treatments [22].
Organoids can be generated from either 1) pluripotent stem
cells, like embryonic stem cells (ESC) and induced pluripo-
tent stem cells (iPSC) or 2) organ-restricted adult stem cells
(aSC) [21]. For the development of endometrial organoids,
aSC are used [17, 23]. As the human endometrium is highly
regenerative, these aSC can be identified in adult endomet-
rial tissue during the process of tissue damage repair and
self-renewal [21, 24]. When conditions that mimic the stem
cell niche environment are created around the aSC, these
stem cells are induced to form organoids [21, 25]. In the
current embedded study, endometrial tissue of women with
unexplained infertility will be developed into endometrial
organoids after broad informed consent. In Reproductive
Medicine these would be the first endometrial organoids
generated from cryopreserved biopsy catheter derived
endometrial tissue. Previous endometrial organoids were
created from fresh, non-frozen biopsy catheter derived tis-
sue or laparoscopically obtained biopsies [17, 23]. The de-
velopment of endometrial organoids will open possibilities
for further research into endometrial receptivity and other
endometrial disorders.
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